Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-097443
Filing Date
2024-11-13
Accepted
2024-11-13 16:01:47
Documents
79
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0216929-10q_oruka.htm   iXBRL 10-Q 1145413
2 FORM OF REGISTRATION RIGHTS AGREEMENT, DATED AS OF AUGUST 29, 2024 ea021692901ex10-4_oruka.htm EX-10.4 100073
3 CERTIFICATION ea021692901ex31-1_oruka.htm EX-31.1 9877
4 CERTIFICATION ea021692901ex31-2_oruka.htm EX-31.2 9911
5 CERTIFICATION ea021692901ex32-1_oruka.htm EX-32.1 6486
  Complete submission text file 0001213900-24-097443.txt   6241428

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE orka-20240930.xsd EX-101.SCH 67909
7 XBRL CALCULATION FILE orka-20240930_cal.xml EX-101.CAL 32124
8 XBRL DEFINITION FILE orka-20240930_def.xml EX-101.DEF 326847
9 XBRL LABEL FILE orka-20240930_lab.xml EX-101.LAB 550245
10 XBRL PRESENTATION FILE orka-20240930_pre.xml EX-101.PRE 336811
81 EXTRACTED XBRL INSTANCE DOCUMENT ea0216929-10q_oruka_htm.xml XML 580186
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 241453876
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)